Elanco Animal Health Logo
US28414H1032
A2N6BH
ELAN

Elanco Animal Health

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 24,19 (-0,49%). A mediana é € 23,59 (-2,96%).

Comprar
  15
Manter
  5
Vender
  2

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Fitch upgrades Elanco after debt reduction and market share gains

    Fitch Ratings has raised Elanco’s long-term issuer default rating from BB to BB+ and upgraded the rating on senior secured obligations to BBB-, with a stable outlook. The agency cites successful debt reductions of about $650 million since 2024, market share gains in the pet health segment, a broad product portfolio and improved cash‑flow generation. Fitch expects leverage to fall (gross leverage toward 3.0x by end‑2027), rising free cash flows through 2028 and EBITDA margins of around 21–22% after 2026. In the near term, freed cash flow is expected to be used primarily for debt repayment, while Elanco invests in product expansion, manufacturing and targeted acquisitions. » Mais em de.investing.com


  • Elanco receives FDA emergency approval for wound spray CLiK Extra against screw-worm fly

    Elanco has received emergency approval from the FDA for the wound spray CLiK Extra, authorized to prevent infestations by the New World screw-worm fly in livestock and certain wild animals. The topical dicyclanil suspension may be used on sheep, cattle, goats, swine, camelids, captive deer, American bison, bighorn sheep and pronghorn, but it does not treat active infestations. Animals of the listed species must not be slaughtered for human consumption within 86 days after treatment; there is no established milk withdrawal period, and the product must not be used on milk-producing animals for human consumption. CLiK Extra will be available through usual veterinary distribution channels and the approval is valid for the duration of the federal emergency. » Mais em de.investing.com


  • Elanco: study shows Credelio Quattro kills black-legged ticks faster than competitors

    Data in Parasites & Vectors show that Credelio Quattro reduces infections with black-legged ticks within 8 hours after treatment, both on day 0 and on day 28 of the dosing interval. Competing products Simparica Trio and NexGard Plus achieved significant reductions only after 12 and 24 hours, respectively, on day 28. Credelio Quattro is FDA-approved for Lyme prevention in dogs; common side effects in studies were vomiting and diarrhea, and the drug class has been linked to neurological effects. » Mais em de.investing.com


  • Elanco projects long-term growth on seven potential blockbusters and $25M venture fund

    TD Cowen raised its price target on Elanco to $32 and cites seven potential blockbuster product launches, a diversified portfolio and pet retail leadership as drivers for projected revenue growth of over 5% and EPS growth of about 10% through 2032. Elanco announced Elanco Ventures, a corporate VC with a $25 million multi-year commitment to invest in Pre-Seed to Series A companies in animal health and One Health, expected to begin operations in late 2026 under Eric Steager. The initiatives aim to bolster future revenue and margin expansion alongside the company’s existing therapeutics and vaccines business. » Mais em finance.yahoo.com


  • Elanco launches $25 million venture fund for animal health

    Elanco has announced Elanco Ventures, a corporate venture platform backed by a multi-year commitment of $25 million to support innovation in animal health. The fund will focus on early-stage investments (pre-seed to Series A) and is scheduled to launch in late 2026; Eric Steager will lead it. Elanco aims to use investments to advance therapeutics, technologies and partnerships under the One Health concept and the One Health Innovation District in Indianapolis. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Elanco Animal Health registou receitas de € 1,12 bi e um ganho líquido de € 15,89 mi
(EUR) setembro de 2026
YoY
Receitas 1,12 bi 15,27%
Ganho bruto 635,65 mi 22,89%
Ganho líquido 15,89 mi 154,85%
EBITDA 73,28 mi 51,69%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 12,14 bi
Número de ações
499,83 mi
Máximo/mínimo de 52 semanas
€ 25,38 - € 17,60
Dividendos Não
Beta
1,72
PER (PE Ratio)
-89,27
PEG (PEG Ratio)
0,09
P/VC (PB Ratio)
2,02
P/V (PS Ratio)
2,60

Perfil da empresa

A Elanco Animal Health Incorporated, uma empresa de saúde animal, inova, desenvolve, fabrica e comercializa produtos para animais de companhia e animais de quinta. Oferece produtos de prevenção de doenças em saúde animal de companhia, como produtos parasiticidas e vacinas que protegem os animais de companhia de vermes, pulgas e carraças, sob as marcas Seresto, Advantage, Advantix e Advocate; terapêuticas para animais de companhia para dor, osteoartrite, infeções de ouvido, indicações cardiovasculares e dermatológicas em cães e gatos, sob as marcas Galliprant e Claro; vacinas, antibióticos, parasiticidas e outros produtos para utilização na produção de aves de capoeira e aquacultura, bem como produtos de saúde nutricional, incluindo enzimas, probióticos e prebióticos; e uma gama de vacinas, antibióticos, implantes, parasiticidas e outros produtos utilizados na produção de ruminantes e suínos, sob as marcas Rumensin e Baytril. A empresa vende os seus produtos a distribuidores terceiros, veterinários e produtores de animais de quinta, incluindo produtores de carne bovina e leiteiros, bem como explorações de suínos, aves de capoeira e aquacultura. A Elanco Animal Health Incorporated foi fundada em 1954 e tem sede em Greenfield, Indiana.

Nome
Elanco Animal Health
CEO
Jeffrey N. Simmons
Sede Indianapolis, in
EUA
Site
Setor
Cuidados de saúde
Indústria
Produtos farmacêuticos
Entrada em bolsa
20/09/2018
Colaboradores 9.650

Símbolos de ticker

Bolsa Símbolo
NYSE
ELAN
Frankfurt
5EA.F
Düsseldorf
5EA.DU
München
5EA.MU
🍪

Parqet  utiliza cookies. Saber mais